Sarasota, FL, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Biotica Pharmaceuticals Inc. (Biotica), an early-stage biotech engaging in the discovery, development, and commercialization of cannabinoid-based medicines for Neuropathic Pain, Cancer, Epilepsy, Autism, Alzheimer's, Parkinson, Esophagitis, and Immune Enhancement, announces today that it has selected Paul R. Carney, M.D. as its Neurologist Consultant and Scientific Advisor effective December 11, 2017. Dr. Carney through his years of research and clinical experience will lead Biotica’s clinical programs.
Dr. Carney has over 20 years of basic translational and clinical research experience in neurological disorders. He is currently Professor and Director for Pediatric Neurosciences at the University of North Carolina at Chapel Hill. Dr. Carney a former Professor at the University of Florida College of Medicine, recently lead the Florida Department of Health sponsored cannabidiol research program. Over the past 20 years, his research has spanned translational basic and clinical research, with a major focus on the development of more effective treatments and diagnostics for epilepsy, cognitive and developmental disorders, and autism spectrum disorders.
Dr. Carney will work closely with Biotica leadership in advancing the research and development objective of the Company. He will be instrumental in supporting the growth of neural disease division at Biotica, and provide strategic direction in developing pre-clinical phase and both clinical phase1 and 2 programs for testing the safety and efficacy of lead drug candidates. He will also advise on cannabinoid regulatory aspects and product pipeline development, and explore avenues for academic-industry collaborations. “We are quite excited to have Paul as our senior scientific advisor. His addition will be huge leap in pushing our drug candidates into the clinical phases” said Sam Talari, Chairman, Biotica Pharmaceuticals.
Biotica Pharma is positioning to be a world-class research and development facility in endocannabinoid drug development. Biotica plans to set-up a state-of-the-art research and development lab to enhance the BPRx platform and rapidly expand its research capabilities. Biotica's research includes specific programs for Alzheimer's disease (BPRx060234), opioid overdose treatment (BPRx060314), eosinophilic esophagitis, Epilepsy, Autism, Parkinson's disease and severe, chronic pain. For each of these diseases, there is a dire need for new therapies. Depending on the disease, our therapies will use a BPRxTM platform to optimize the synergistic combination of photo and endocannabinoids to modulate disease pathology and progression. By significantly decreasing the production of relevant signaling and causative molecules at targeted sites within various tissue systems, the goal is to address the underlying biology of the disease and make a meaningful difference for patients. Our talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.
About Biotica Pharmaceuticals Inc.
Biotica Pharmaceuticals, a Delaware company, is an early-stage biotech founded by a group of pioneers in cannabis technology landscape. Biotica, a biopharmaceutical company, together with its subsidiaries, will engage in discovering, developing, and commercializing cannabinoid-based medicines. It will operate through three segments: 1) Commercial, 2) Drug delivery systems and methods such as hydrophobic, 3) Cannabinoids Research and Development for Neuropathic pain, Cancer, Alzheimer's, Parkinson, Esophagitis, and Immune Enhancement. Currently Biotica has one location in Florida and soon plans to add a second facility housing the lab in the State of Florida.
To request further information about Biotica Pharmaceuticals, please email us at info@bioticapharma.com, log onto our website at http://www.bioticapharma.com or visit us at our Facebook page facebook.com/bioticapharma or on Twitter @bioticapharma.
Forward-Looking Statements
This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.